You are here

Folate Receptor Therapy Vintafolide Shows Promise in Ovarian Cancer

Treatment improves progression-free survival (October 14)

The Journal of Clinical Oncology has reported positive results from a phase II trial of vintafolide (Merck), an investigational folate small-molecule drug conjugate (SMDC).

The PRECEDENT study showed that the administration of vintafolide plus pegylated liposomal doxorubicin (PLD) in women with platinum-resistant ovarian cancer resulted in a median progression-free survival (PFS) of 5.0 months compared with 2.7 months for those treated with PLD alone (hazard ratio [HR], 0.63; P = 0.031).

Patients with folate receptor-positive tumors demonstrated greater benefit, as measured by PFS, from treatment with vintafolide plus PLD versus PLD alone. The median PFS in these patients was 5.5 months compared with 1.5 months for those treated with PLD alone (HR, 0.38; P = 0.013).

Vintafolide is an investigational, injectable folate SMDC consisting of folate (vitamin B9) linked to a vinca alkaloid chemotherapy agent, desacetylvinblastine hydrazide (DAVLBH). Vintafolide is designed to direct DAVLBH to rapidly growing cancer cells that actively take up folate via the folate receptor. The folate receptor is expressed in a wide variety of cancers, including ovarian cancer.

Source: Merck; October 14, 2013.

Recent Headlines

Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs